The stepwise entry of variables in the model and continuation in the final model were determined by their relevance and PI3K Inhibitor Library statistical significance (p < 0.20 and p < 0.05, respectively). This study was approved by the Ethics in Research

Committees of the National School of Public Health-Fiocruz (document 236A/03 CEP-FIOCRUZ), and the Ministry of Health of the Federal District (Document SES-DF CEP-069/2005) authorized by ANVISA and registered in the International Standard Randomised Controlled Trial Number Register (ISRCTN 72367932). From a total of 1943 children, 115 in one health center were disregarded in the analysis because of inconsistencies in identification numbers of blood samples. All the remaining 1828 children received the MMR (Bio-Manguinhos/GSK, 48.5%, Merck, 35.6%, not recorded, 15.9%) and 59 (3.2%) did not receive yellow fever vaccine in the study. In the intention-to-treat analysis, MAPK inhibitor we included the 1769 children who received yellow fever vaccine, and were thus randomly assigned to one type of YFV. Among those, 22 (1.2%) did not return for blood sampling after vaccination. Of those who returned, 43 (2.5%), 54 (3.1%), 56 (3.2%) and 24 (1.4%) did not have post-vaccination

serological status for rubella, measles, mumps and yellow fever, respectively (Fig. 1). The total loss was 13.5% and included subjects who did not return for vaccination or blood collection, or whose specimens were lost or were insufficient to perform the serological tests. These losses were not selective regarding study groups. Six children assigned to vaccination with an interval of 30 days received the Modulators vaccines simultaneously, whereas in 5 children the opposite occurred. The 59 volunteers Linifanib (ABT-869) lost between the two randomization procedures were similar to those volunteers randomized to the vaccine against yellow fever, according to gender, age weight, and the proportion seropositive for rubella and yellow fever (Table 1). The base-line characteristics were well-balanced across comparison groups (Table 1). The proportion of children seropositive

to yellow fever before vaccination was substantially higher than for measles, mumps and rubella. The proportion of seroconversion and magnitude of immune response (GMT and distribution of postvaccination antibody titers) for rubella were substantially higher in the group in which YFV and MMR were given 30 days apart, compared to those vaccinated simultaneously (p < 0.001, Table 2 and Fig. 2). In contrast, the groups defined by the types of yellow fever vaccines showed no significant differences in immune response (p > 0.5, Table 2 and Fig. 2). In the logistic model for seroconversion only the interval between vaccines showed a statistically significant association (OR = 3.80, 95% CI: 2.39–6.05).